Our results

The pandemic forced healthcare professionals and pharmaceutical companies to adapt to new technologies, but HCP engagement with pharma decreased by 15% due to over-saturation and lack of meaningful integration.

Pivot used a data-driven approach and cross-functional collaboration to identify the root causes of poor engagement with neurologists during the pandemic and create an innovative approach to customer interactions, resulting in higher activity and more high-value interactions, as well as winning a marketing award.

The healthcare industry is experiencing a major transformation, with new technologies and approaches paving the way for innovative healthcare systems that are more patient-centric, data-driven, and collaborative than ever before.

Digital therapeutics (DTx) have seen a surge in investment, but there has been limited tangible impact on patient care. The industry needs to develop action-oriented plans to unlock the potential of DTx and create better care standards. In 2023, we will likely see a shift towards collaborations that create valued integrative therapies, particularly within chronic care, oncology and mental health.

In 2023, the pharma and life sciences industry will continue to use data analytics to transform scientific innovation and customer engagement. To make a real impact, companies should focus on taking action based on insights and upgrading CRM systems to effectively use behavioral data and increase sales.